Branka Radic Sarikas
Branka Radic Sarikas
Medical University of Vienna and St. Anna CCRI Children's Cancer Research Institute
Verified email at - Homepage
Cited by
Cited by
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
KVM Huber, E Salah, B Radic, M Gridling, JM Elkins, A Stukalov, ...
Nature 508 (7495), 222-227, 2014
The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity
GE Winter, B Radic, C Mayor-Ruiz, VA Blomen, C Trefzer, RK Kandasamy, ...
Nature chemical biology 10 (9), 768-773, 2014
Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions
R Martins, J Maier, AD Gorki, KVM Huber, O Sharif, P Starkl, S Saluzzo, ...
Nature immunology 17 (12), 1361-1372, 2016
The YAP/TAZ pathway in osteogenesis and bone sarcoma pathogenesis
H Kovar, L Bierbaumer, B Radic-Sarikas
Cells 9 (4), 972, 2020
The second European interdisciplinary Ewing sarcoma research summit–A joint effort to deconstructing the multiple layers of a complex disease
H Kovar, J Amatruda, E Brunet, S Burdach, F Cidre-Aranaz, E De Alava, ...
Oncotarget 7 (8), 8613, 2016
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells
L Bierbaumer, AM Katschnig, B Radic-Sarikas, MO Kauer, JA Petro, ...
Oncogenesis 10 (1), 2, 2021
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
B Radic-Sarikas, M Halasz, KVM Huber, GE Winter, KP Tsafou, ...
Scientific Reports 7 (1), 3091, 2017
Histone deacetylase inhibitors: clinical implications for hematological malignancies
FP Tambaro, C Dell’Aversana, V Carafa, A Nebbioso, B Radic, F Ferrara, ...
Clinical epigenetics 1, 25-44, 2010
The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells
G Franci, L Casalino, F Petraglia, M Miceli, R Menafra, B Radic, V Tarallo, ...
Biology open 2 (10), 1070-1077, 2013
Combinatorial drug screening identifies Ewing sarcoma–specific sensitivities
B Radic-Sarikas, KP Tsafou, KB Emdal, T Papamarkou, KVM Huber, ...
Molecular Cancer Therapeutics 16 (1), 88-101, 2017
Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
K Tsafou, AM Katschnig, B Radic-Sarikas, CN Mutz, K Iljin, R Schwentner, ...
Oncotarget 9 (57), 31018, 2018
Zooming in on long non-coding RNAs in ewing sarcoma pathogenesis
DNT Aryee, V Fock, U Kapoor, B Radic-Sarikas, H Kovar
Cells 11 (8), 1267, 2022
High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma
S Grissenberger, C Sturtzel, A Wenninger-Weinzierl, B Radic-Sarikas, ...
Cancer Letters 554, 216028, 2023
Enhancing cognate target elution efficiency in gel-free chemical proteomics
B Radic-Sarikas, U Rix, A Stukalov, M Gridling, AC MŘller, J Colinge, ...
EuPA Open Proteomics 9, 43-53, 2015
Targeting YAP/TAZ pathway inhibits Ewing sarcoma metastasis
L Bierbaumer, AM Katschnig, B Radic-Sarikas, JR Petro, K MŘhlbacher, ...
Cancer Research 79 (13_Supplement), 1049-1049, 2019
In vitro modeling of pediatric solid tumor lung metastases
M Zylka, C Hafemeister, L Watzke, U Mann, D Surdez, EA Sweet-Cordero, ...
Cancer Research 84 (6_Supplement), 196-196, 2024
3D-models of pediatric bone sarcomas for personalized therapeutic screening
B Radic Sarikas, M Ilg, M Markovic, C Sturtzel, E Scheuringer, J Zulini, ...
3D-models of pediatric bone sarcomas for personalized therapeutic screening
BR Sarikas, M Ilg, M Markovic, C Sturtzel, E Scheuringer, J Zulini, ...
Cancer Research 82 (12_Supplement), 6245-6245, 2022
Targeted Therapy
H Gad, T Koolmeister, AS Jemth, S Eshtad, SA Jacques, CE Str÷m, ...
cancer strategy 508, 222-7, 2014
Elucidating the molecular mechanism of action of cancer drugs in the second decade of the new millennium
G Superti-Furga, G Winter, J Bigenzahn, B Radic, J Colinge, K Bennett, ...
Experimental Hematology 41 (8), S9, 2013
The system can't perform the operation now. Try again later.
Articles 1–20